

Title (en)  
INTERFERON-EPSILON

Title (de)  
INTERFERON EPSILON

Title (fr)  
INTERFERON-EPSILON

Publication  
**EP 1141296 A2 20011010 (EN)**

Application  
**EP 99969444 A 19990916**

Priority  
• US 9921279 W 19990916  
• US 15706898 A 19980918  
• US 24529399 A 19990205  
• US 35023299 A 19990708

Abstract (en)  
[origin: WO0017361A2] Interferons represent an important class of biopharmaceutical products, which have a proven track record in the treatment of a variety of medical conditions, including the treatment of certain autoimmune diseases, the treatment of particular cancers, and the enhancement of the immune response against infectious agents. To date, four types of interferons have been found in humans: interferon- alpha , interferon- beta , interferon- gamma , and interferon- omega . The present invention provides new forms of human and murine interferon, "interferon- epsilon ", which have applications in diagnosis and therapy.

IPC 1-7  
**C12N 15/20**; C07K 14/555; C12N 15/62; C07K 16/24; A61K 38/21; C12Q 1/68; C12N 7/01; A61K 31/70; C12N 5/10; A61K 48/00

IPC 8 full level  
**C12N 15/20** (2006.01); **G01N 33/53** (2006.01); **A61K 35/76** (2006.01); **A61K 38/00** (2006.01); **A61K 38/21** (2006.01); **A61K 48/00** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01); **A61P 15/08** (2006.01); **A61P 25/00** (2006.01); **A61P 25/16** (2006.01); **A61P 25/18** (2006.01); **A61P 25/22** (2006.01); **A61P 25/24** (2006.01); **A61P 25/28** (2006.01); **A61P 29/00** (2006.01); **A61P 31/12** (2006.01); **A61P 31/18** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **A61P 37/02** (2006.01); **A61P 37/04** (2006.01); **C07K 14/555** (2006.01); **C07K 16/00** (2006.01); **C07K 16/24** (2006.01); **C07K 19/00** (2006.01); **C12N 1/15** (2006.01); **C12N 1/19** (2006.01); **C12N 1/21** (2006.01); **C12N 5/10** (2006.01); **C12N 7/00** (2006.01); **C12N 15/09** (2006.01); **C12N 15/62** (2006.01); **C12P 21/02** (2006.01); **C12P 21/08** (2006.01); **C12Q 1/02** (2006.01); **C12Q 1/68** (2006.01)

CPC (source: EP)  
**A61P 9/00** (2017.12); **A61P 9/10** (2017.12); **A61P 15/08** (2017.12); **A61P 25/00** (2017.12); **A61P 25/16** (2017.12); **A61P 25/18** (2017.12); **A61P 25/22** (2017.12); **A61P 25/24** (2017.12); **A61P 25/28** (2017.12); **A61P 29/00** (2017.12); **A61P 31/12** (2017.12); **A61P 31/18** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 37/02** (2017.12); **A61P 37/04** (2017.12); **C07K 14/555** (2013.01); **A61K 38/00** (2013.01); **A61K 48/00** (2013.01); **C07K 2319/00** (2013.01); **C12N 2799/021** (2013.01)

Citation (search report)  
See references of WO 0017361A2

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 0017361 A2 20000330**; **WO 0017361 A3 20010726**; AU 6042599 A 20000410; CA 2342773 A1 20000330; EP 1141296 A2 20011010; IL 142061 A0 20020310; JP 2002526078 A 20020820

DOCDB simple family (application)  
**US 9921279 W 19990916**; AU 6042599 A 19990916; CA 2342773 A 19990916; EP 99969444 A 19990916; IL 14206199 A 19990916; JP 2000574260 A 19990916